Sentences with phrase «signaling protein interactions»

The vast majority of the thousands of potential membrane protein - signaling protein interactions they found had never before been identified.

Not exact matches

Gold nanoparticles provide bigger surface area for the affinity interactions between the antibody - antigen and thus enhance the translated signal, while the antifouling molecules help to resist the non-specific adsorption of unwanted proteins from serum onto the transducer surface.

But when I discussed my aspirations with established PIs — who had spent their careers learning everything they could about a particular gene or protein — I probably seemed lazy or uninterested, because I couldn't specify a particular signaling pathway or molecule - ligand interaction that I wanted to study.

Bohn noted isoquinolinone 2.1 is one example of a new class of «biased» kappa agonists that avoid many central nervous system side effects by preferentially activating a G protein - mediated signaling cascade without involving another system based on β - arrestin protein interactions.

The team also identified genes that had not been previously linked to ASD, but are heavily involved in numerous protein interactions and signaling pathways.

This study reveals how lipids control SH2 domain - mediated cellular protein interaction networks and suggests a new strategy for the therapeutic modulation of pY - signaling pathways.

Protein interactions between niche glial cells and the stem cells activate the Hippo signaling pathway in the stem cells to repress growth and cell division.

To figure out how signalling pathways work, molecular biologists carry out and validate experiments, sometimes over many years, to characterise the exact interactions taking place between proteins.

In Science (512 December, 2003; 302: 1984 - 1988) he described the first known longitudinal signals: Wnt proteins, which are known to regulate cell - cell interactions in embryonic development.

Cell signaling pathways are a defined series of interactions between proteins that govern biological functions, initiated by receptors on the surface of cells.

Toll / interleukin -1 receptor (TIR) domain - containing proteins play important roles in defense against pathogens in both animals and plants, connecting the immunity signaling pathways via a chain of specific protein - protein interactions.

Timothy Springer, with colleagues Michael L. Dustin and Charles A. Dinarello, identifies and characterizes adhesion molecules, a class of cell surface proteins that function in the interactions of immune cells with other cells, including antigen - specific recognition and cell trafficking: integrin LFA - 1 involved in cytoskeleton and signaling, and intracellular adhesion molecules (ICAMs), which are binding partners (ligands) for LFA - 1 and are increased in inflammatory and autoimmune disease.

Estrogen receptor protein interaction with phosphatidylinositol 3 - kinase leads to activation of phosphorylated Akt and extracellular signal - regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action.

The SDF - 1 / CXCR4 interaction stimulates tyrosine phosphorylation of CXCR4, followed by the activation of multiple G protein - dependent signaling pathways, which may be different among cell types.

We invite original innovative research on the rational engineering of plant systems at all levels, including proteins, protein complexes, sensors, metabolic and signalling pathways, microcompartments such as carboxysomes, subcellular compartments, cell types or tissues, as well as the engineering of novel plant hybrid species and the interactions of plants with viruses, bacteria, and other organisms.

8.30 Hana Paculová CDK12 connects transcriptional regulation to DNA damage repair pathway 8.55 Karol Kaiser Wnt secretion during nervous system development 9.20 Simona Hankeová The role of Notch signaling in vasculogenesis 10.00 Coffee break 10.30 Tomáš Doležal Extracellular adenosine regulates complex host - pathogen interactions through the energy release for the immune response 10.55 Ondřej Bernatík and Igor Červenka Regulation of diverse function of Dvl by phosphorylation 11.20 Jan Ryneš Dissection of Axin interactome: rational approach for control of signaling cascades via intervention with specific protein - protein interactions 12.05 Targeting opportunities: discussion & sum - up 13.00 Lunch and departure

Even though transient and weak it is becoming more and more obvious that lipid protein interactions are the key for many regulatory processes in which specific protein complexes have to be formed for example upon stimuli during cell signaling.

De novo rational design of molecular scaffolds mimicking protein interactions for specific interference in cell signaling processes: We apply molecular modelling and computer simulation techniques for designing molecules with pharmacological / biotechnological interest.

Beyond the internal interactions of the protein itself, these designed oligomers can be used to explore basic questions about how the structure of signaling molecules affects the behavior of receptors and cellular response.

Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) traSignaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trasignaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trasignaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trasignaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Santini E, Huynh TN, Longo F, Koo SY, Mojica E, D'Andrea L, Bagni C, Klann E. (2017) Reducing eIF4E - eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.Sci Signal.

For the interaction and network data we used three detailed signalling network resources, SignaLink 2,25 Reactome, 26 and a cancer signalling network compiled by Cui et al. 10, as well as two more global protein - protein interaction (PPI) networks, namely the manually curated HPRD, 27 resource and the integrated dataset comprising DIP, 28 IntAct, 29 and BioGrid.30 All these networks have different compilation protocols and thereby provide partially different information.

To understand the selection mechanism behind mutations, network - based studies were used to estimate the importance of a mutated protein compared to non-mutated ones in signalling and protein — protein interaction networks.10, 11,12,13 Proteins mutated in cancer were found having a high number of interacting partners (i.e., a high degree of connectivity), which indicates high local importance.10 Mutated proteins are also often found in the centre of the network, in key global positions, as quantified by the number of shortest paths passing through them if all proteins are connected with each other (i.e., they have high betweenness centrality; hereafter called betweenness).11, 12 Mutated proteins also have high clustering coefficients, which means their neighbours are also neighbours of each other.10, 13 Moreover, neighbourhood analysis of mutated proteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets theProteins mutated in cancer were found having a high number of interacting partners (i.e., a high degree of connectivity), which indicates high local importance.10 Mutated proteins are also often found in the centre of the network, in key global positions, as quantified by the number of shortest paths passing through them if all proteins are connected with each other (i.e., they have high betweenness centrality; hereafter called betweenness).11, 12 Mutated proteins also have high clustering coefficients, which means their neighbours are also neighbours of each other.10, 13 Moreover, neighbourhood analysis of mutated proteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets theproteins are also often found in the centre of the network, in key global positions, as quantified by the number of shortest paths passing through them if all proteins are connected with each other (i.e., they have high betweenness centrality; hereafter called betweenness).11, 12 Mutated proteins also have high clustering coefficients, which means their neighbours are also neighbours of each other.10, 13 Moreover, neighbourhood analysis of mutated proteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets theproteins are connected with each other (i.e., they have high betweenness centrality; hereafter called betweenness).11, 12 Mutated proteins also have high clustering coefficients, which means their neighbours are also neighbours of each other.10, 13 Moreover, neighbourhood analysis of mutated proteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets theproteins also have high clustering coefficients, which means their neighbours are also neighbours of each other.10, 13 Moreover, neighbourhood analysis of mutated proteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets theproteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets theproteins in cancer, and their usefulness as drug targets themselves.

The successful candidate will receive extensive training on proteomics - based discovery (secretome proteomics to identify cytokines important in different children's cancers, protein expression profiling of subcellular fractions and organelles, and interactome proteomics to identify novel protein — protein interactions) and follow - up of proteomic findings (molecular cell biological characterization of protein functions and signaling).

Use Proteomics techniques to identify, signaling pathways, protein interactions, protein modifications.